Read my earlier posts Twinturbo. VLA need US$300k per month just to keep the lights on and VLA have no cash. This leaves them with around $7mill of option/convertible note funding over the next 2 years to fund an FDA approved phase II. There is no way they will be able to conduct a decent sized phase II trial with $7mill. $25mill is more in the ball park, which leaves them with a $15-20mill shortfall. VLA management would have to have rocks in their head not to take advantage of this price spike and conduct a raising or at least put in place another dilution financing instrument.
$55mill is a huge EV for a phase I biotech without sufficient funding in place, and VLA management would know this.
Day traders might push this thing higher in the short term, but just remember, a sensible short term valuation for VLA, all things considered, is around 5-7c.
And if The Speculator is true to form, he will lock in profits tomorrow.
VLA Price at posting:
12.0¢ Sentiment: ST Sell Disclosure: Not Held
